Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500578 · ClinicalTrials.gov registry record · Phase 4
Intermittent Use of Aerosolized Ribavirin for Treatment of RSV
A Phase 4 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT00500578: Completed Phase 4 study, sponsored by M.D. Anderson Cancer Center.
NCT00500578 is a Phase 4 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00500578, a Phase 4 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
Primary Objectives: 1. To determine whether aerosolized ribavirin is effective when given at an intermittent dose over 3 hours every 8 hours for therapy of RSV upper respiratory tract infection (URI) and whether it can prevent progression to pneumonia. 2. To determine the effect of this regimen on persistence of viral shedding.
Interventions
- DRUG Ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2003-02 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00500578
The ClinicalTrials.gov registry entry for NCT00500578 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ribavirin is the first listed.
NCT00500578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00500578 about?
NCT00500578 is a clinical study titled "Intermittent Use of Aerosolized Ribavirin for Treatment of RSV". Primary Objectives: 1. To determine whether aerosolized ribavirin is effective when given at an intermittent dose over 3 hours every 8 hours for therapy of RSV upper respiratory tract infection (URI) and whether it can prevent progression to pneumonia. 2. To determine the effect of this regimen on ...
What is the current status of trial NCT00500578?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2003-02. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00500578?
The interventions under investigation include: Ribavirin (DRUG).
Who is sponsoring clinical trial NCT00500578?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.